MCM
MPLT

MAI Capital Management’s MapLight Therapeutics MPLT Stock Holding History

MAI Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$244 – 5071
2026
Q1 		$244 Buy
+12
New +$215 ﹤0.01% 4578

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's MPLT Position: Q2 2026 in Review

MAI Capital Management sold out of MapLight Therapeutics (MPLT) in Q2 2026, closing a stake of 12 shares — an estimated $244 sold.

MAI Capital Management first reported a position in MPLT in Q1 2026 and held it in 1 quarter. The position peaked at $244 in Q1 2026. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • MAI Capital Management reported no remaining MapLight Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 12 MapLight Therapeutics shares in Q2 2026, an estimated $244.
  • MAI Capital Management first reported a position in MapLight Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's MapLight Therapeutics position peaked at $244 in Q1 2026.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.